Mumbai, India

Glenmark Generics Limited

USPTO Granted Patents = 9

% Expired Patents = 88.9



Forward Citations = 4

Loading Chart...
Loading Chart...

30 inventors (with patents filed for the assignee):

goldMedal Mubeen Ahmed Khan (4 out of 5 patents)

silverMedal Nitin Sharad Chandra Pradhan (3 out of 5 patents)

bronzeMedal Shekhar Bhaskar Bhirud (2 out of 28 patents)

4.  Sukumar Sinha (2 out of 8 patents)

5.  Sanjay Anantha Kale (2 out of 2 patents)

6.  Sankar Arjunan (2 out of 2 patents)

7.  Sharad R Gore (1 out of 3 patents)

8.  Prem Chand (1 out of 3 patents)

9.  Krishna Baban Narawade (1 out of 2 patents)

10.  Mangesh Shivram Sawant (1 out of 3 patents)

11.  Mubeen Ahmad Khan (1 out of 2 patents)

12.  Milind Gharpure (1 out of 2 patents)

13.  Nikhil Rasiklal Trivedi (1 out of 2 patents)

14.  Nagan Nirmalan Kandasamy (1 out of 1 patent)

15.  Vipin Kumar Pandey (1 out of 1 patent)


9 patents:

Company Overview
Glenmark Pharmaceuticals is a global pharmaceutical company that strives to improve the quality of life by providing affordable medicines. They have a subsidiary called Glenmark Generics Limited that focuses on developing and manufacturing generic pharmaceutical products. With a strong manufacturing and research infrastructure, Glenmark Generics Limited aims to make healthcare accessible to all.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

9 Patents

#35 in Mumbai

#185 in India

Mumbai, IN
Mumbai, India
Forward Citations = 4

30 inventors:

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Glenmark Generics Limited. Retrieved from https://idiyas.com/company/glenmark-generics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…